Healthcare
Live Price
Offline$0.189
+11.83% today
1Y Change
-67.90%
Window
Jun 23, 2025 → Jun 5, 2026
Coverage: 241 bars · Jun 23, 2025 → Jun 5, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ZyVersa Therapeutics, Inc. (ZVSA) is a Healthcare stock with listed on OTC. The stock last traded around $0.19 and down 67.9% across the available one-year price window (Jun 23, 2025 → Jun 5, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +50.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +50.7%, free cash flow -67553.3% with operating margin 0.0% and ROIC 0.1%. Stock Foundry combines ZVSA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZVSA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ZVSA Max Drawdown
-85.16%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ZVSA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$8.1M
+42.5% YoY
Free Cash Flow
-$5.1M
-239.6% YoY
Revenue Growth
+0.0%
EPS Growth
+50.7%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | -7K | -10K | -10K | -10K |
| Operating Income | -25.5B | -9.1B | -14M | -14M | -8M |
| EBITDA | -25M | -9.1B | -108M | -14M | -7M |
| Net Income | -25.0B | -9.4B | -98M | -14M | -8M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 102M | 2M | 3M | 6M | 329K |
| Total Assets | 348M | 21M | 22M | 119M | 1M |
| Total Liabilities | 12.7B | 12M | 11M | 19M | 14M |
| Shareholder Equity | -12.4B | 9M | 11M | 100M | -13M |
| Total Debt | 0 | 0 | 9K | 109K | 9M |
| Net Debt | -102M | -2M | -3M | -6M | 9M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
5M
-3.8% YoY
Capital Expenditures
0
Free Cash Flow
5M
-239.6% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
0.8%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.